Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaci.2014.03.019PMID 24797423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sublingual immunotherapy: World Allergy Organization position paper 2013 update

  2014cited by this paper
• SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

  2012cited by this paper
• Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence.

  2012cited by this paper
• Sublingual immunotherapy: allergen specific or placebo effect?

  2011cited by this paper
• Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults.

  2011cited by this paper
• Rhinitis , sinusitis , and upper airway disease Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen – induced rhinoconjunctivitis

  2011cited by this paper
• Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.

  2011cited by this paper
• Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial.

  2010cited by this paper
• Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study.

  2010cited by this paper
• Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

  2010cited by this paper
• Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

  2010cited by this paper
• Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.

  2009cited by this paper
• An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.

  2009cited by this paper
• Sub-Lingual Immunotherapy

  2009cited by this paper
• Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis

  2009cited by this paper
• A Population-based Clinical Study of Allergic and Non-allergic Asthma

  2009cited by this paper
• Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

  2009cited by this paper
• Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *

  2008cited by this paper
• Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.

  2008cited by this paper
• Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.

  2007cited by this paper
• Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study

  2007cited by this paper
• Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children

  2007cited by this paper
• Anti-IgE for chronic asthma in adults and children.

  2006cited by this paper
• Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

  2006cited by this paper
• Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.

  2006cited by this paper
• Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis

  2006cited by this paper
• Steroid‐sparing effect of subcutaneous SQ‐standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics

  2006cited by this paper
• Anti-IgE for chronic asthma in adults and children.

  2006cited by this paper
• The global burden of asthma: executive summary of the GINA Dissemination Committee Report

  2004cited by this paper
• Prevalence and rate of diagnosis of allergic rhinitis in Europe

  2004cited by this paper
• Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey

  2002cited by this paper
• The link between allergic rhinitis and allergic asthma: A prospective population‐based study. The Copenhagen Allergy Study

  2002cited by this paper
• ICH Harmonised Tripartite Guideline: guideline for good clinical practice.

  2001cited by this paper
• Measuring asthma control. Clinic questionnaire or daily diary?

  2000cited by this paper
• Allergen immunotherapy: does it work and, if so, how and for how long?

  2000cited by this paper
• Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline.

  1999cited by this paper
• Allergen immunotherapy: therapeutic vaccines for allergic diseases

  1998cited by this paper
• Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.

  1998cited by this paper
• Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997.

  1998cited by this paper
• GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

  1996cited by this paper
• Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy.

  1995cited by this paper
• Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.

  1992cited by this paper

• The Spanish REAL project: expert allergist guidance on allergen immunotherapy based on mixtures from different allergenic sources

  2026cites this paper
• Adherence and Effect on Allergy Medication Use in Allergic Rhinoconjunctivitis Patients Treated With House Dust Mite Allergen Immunotherapy-A Nationwide Cohort Study.

  2026cites this paper
• SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial

  2025cites this paper
• Targeted treatment in asthma - opportunities and challenges.

  2025cites this paper
• Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes

  2025cites this paper
• The Efficacy of Sublingual Immunotherapy in Patients With House Dust Mite Allergic Asthma—A Systematic Review

  2025cites this paper
• Disease burden in children with moderate to severe perennial allergic rhinitis and concomitant asthma in Canada, Denmark, and the United Kingdom

  2025cites this paper
• Сoncentration dynamics of allergen-specific sIgA in saliva, IL-4 and IFN-γ in blood serum as a predictive biomarker of the allergen immunotherapy efficacy

  2025cites this paper
• The Role of Environmental Exposures in Pediatric Asthma Pathogenesis: A Contemporary Narrative Review

  2025cites this paper
• Allergen immunotherapy: effective on lung function?

  2025cites this paper
• Patients’ perspective on allergen immunotherapy for respiratory allergy

  2025cites this paper
• Long‐Term, Real‐World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma

  2025cites this paper
• Hybrid Adjuvant-Allergen H1sD2 Proteoforms Enhance Innate Immunity Activation via Distinct N-Glycosylation Profiles

  2025cites this paper
• Immunotherapy for asthma

  2025cites this paper
• Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial

  2024cites this paper
• Allergen Immunotherapy: Optimal Duration for Respiratory Allergy

  2024cites this paper
• Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)

  2024cites this paper
• Allergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)

  2024cites this paper
• Allergen immunotherapy for allergic asthma

  2024cites this paper
• Allergen-specific immunotherapy for allergic asthma: What’s new?

  2024cites this paper
• Allergen immunotherapy in asthma.

  2024cites this paper
• The evidence for commercial house dust mite immunotherapy products: A pragmatic systematic review with narrative synthesis

  2024cites this paper
• Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis

  2024cites this paper
• The Combination of Allergen Immunotherapy and Biologics for Inhalant Allergies: Exploring the Synergy.

  2024cites this paper
• Novel Approaches to Allergen Immunotherapy for Respiratory Allergies

  2024cites this paper
• Allergen Immunotherapy for the Prevention and Treatment of Asthma

  2024cites this paper
• Allergen immunotherapy

  2024cites this paper
• Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.

  2024cites this paper
• The pharmacotherapeutic management of allergic rhinitis in people with asthma

  2024cites this paper
• Sublingual allergen immunotherapy (SLIT) prevents house dust mite inhalant type 2 immunity through DC-mediated induction of Foxp3+ regulatory T cells.

  2024cites this paper
• Real-world evidence of allergen immunotherapy

  2024cites this paper
• Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma.

  2024cites this paper
• Medical algorithm: Diagnosis and treatment of house dust mite‐driven allergic asthma

  2023cites this paper
• Grand Rounds Review Article: "Allergen immunotherapy for asthma".

  2023cites this paper
• Asthma.

  2023cites this paper
• Allergen immunotherapy for allergic asthma - The future seems bright.

  2023cites this paper
• How can we improve our use of allergen immunotherapy as a treatment option for asthma and severe asthma?

  2023cites this paper
• Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma

  2023cites this paper
• The KAAACI Guidelines for Sublingual Immunotherapy

  2023cites this paper
• Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.

  2023cites this paper
• PREVENTION IS BETTER THAN CURE: IMPACT OF ALLERGEN IMMUNOTHERAPY ON THE PROGRESSION OF AIRWAY DISEASE.

  2023cites this paper
• Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling.

  2023cites this paper
• Hot topics in allergen immunotherapy, 2023: Current status and future perspective

  2023cites this paper
• KAAACI Guidelines for Allergen Immunotherapy

  2023cites this paper
• Short-term and long-term efficacy of sublingual immunotherapy in different courses for house dust mite-induced allergic rhinitis.

  2023cites this paper
• SQ HDM sublingual immunotherapy tablet for the treatment of HDM allergic rhinitis and asthma improves subjective sleepiness and insomnia: an exploratory analysis of the real-life CARIOCA study.

  2023cites this paper
• Approaches to Management of Asthma: Guidelines for Stepped Care and Self-Monitoring.

  2023cites this paper
• Advancing Precision Medicine in Asthma: Evolution of Treatment Outcomes.

  2023cites this paper
• Allergen immunotherapy: progress and future outlook

  2023cites this paper
• Potential Effects of AIT on Nonspecific Allergic Immune Responses or Symptoms

  2023cites this paper
• Allergic asthma: An indication for allergen immunotherapy

  2023cites this paper
• S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023

  2023cites this paper
• Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper

  2023cites this paper
• Efficacy of Sublingual Immunotherapy in Allergic Rhinitis Patients with Asthma: A Systematic Review and Meta-Analysis

  2023cites this paper
• Comparison of National and Global Asthma Management Guiding Documents

  2022cites this paper
• Barriers to accessing aeroallergen immunotherapy in paediatrics

  2022cites this paper
• Allergen immunotherapy for respiratory allergies in clinical practice: A comprehensive review.

  2022cites this paper
• EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

  2022cites this paper
• Guideline on allergen immunotherapy in IgE-mediated allergic diseases

  2022cites this paper
• Leitlinie zur Allergen-Immuntherapie bei IgE-vermittelten allergischen Erkrankungen

  2022influential citation
• Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy.

  2022cites this paper
• Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets

  2022cites this paper
• Immunotherapy for Asthma.

  2022cites this paper
• Allergen immunotherapy: past, present and future

  2022cites this paper
• Federal guidelines on diagnosis and treatment of bronchial asthma

  2022cites this paper
• Allergen-Specific Immunotherapy

  2022cites this paper
• Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study

  2022cites this paper
• House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis.

  2022influential citation
• Delivery options for sublingual immunotherapy for allergic rhinoconjunctivitis: clinical considerations for North America

  2022cites this paper
• Efficacy and safety of house dust mite sublingual immunotherapy tablet in allergic asthma: A systematic review of randomized controlled trials.

  2022cites this paper
• Maintained disease control and steroid-sparing effect of subcutaneous immunotherapy in allergic rhinitis and asthma.

  2022cites this paper
• The SQ HDM SLIT‐Tablet is safe and well tolerated in patients with House Dust Mite allergic rhinitis with or without asthma: A “real‐life” French study

  2022cites this paper
• Which patients with asthma are most likely to benefit from allergen immunotherapy?

  2022cites this paper
• Allergen immunotherapy for long-term tolerance and prevention.

  2022cites this paper
• Cost‐effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma

  2022cites this paper
• Extrapolating Evidence Based Medicine of AIT into Clinical Practice in the US.

  2022cites this paper
• Allergen immunotherapy in treating allergic eosinophilic asthma.

  2022cites this paper
• Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis.

  2022cites this paper
• Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.

  2021cites this paper
• Effectiveness and safety of oral lactococci-based vaccine encoding triple common allergens to prevent airway allergy in mice

  2021cites this paper
• Efficacy of Allergen Specific Immunotherapy for Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis

  2021cites this paper
• SUBLINGUAL ALLERGEN IMMUNOTHERAPY AND ALLERGIC ASTHMA: A PRO AND CON REVIEW.

  2021cites this paper
• Current treatment options for allergies in children

  2021cites this paper
• New insights in mite immunotherapy – sublingual tablets

  2021cites this paper
• How important is proper dosing for subcutaneous and sublingual allergy immunotherapy?

  2021cites this paper
• Současné možnosti léčby alergie u dětí

  2021cites this paper
• [Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version].

  2021cites this paper
• 2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges.

  2021cites this paper
• Management of adult asthma and chronic rhinitis as one airway disease

  2021cites this paper
• The Current State of Safety of Allergen Immunotherapy

  2021cites this paper
• Immunotherapy for Allergy

  2021cites this paper
• Recent Advances in Allergen-Specific Immunotherapy as Treatment for Allergic Asthma: A Practical Overview

  2021cites this paper
• A Real-Life One-Year Non-Interventional Study Assessing Safety, Tolerability, and Treatment Outcome of the SQ HDM SLIT-Tablet (Acarizax®) in House Dust Mite Allergic Rhinitis With or Without Asthma

  2021cites this paper
• Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology

  2021cites this paper
• Benefit Effect of Sublingual Dust Mite Drops on the Control of Asthma in Children

  2021cites this paper
• Allergen Immunotherapy in Asthma

  2021cites this paper
• Current Drug Treatments for Allergy

  2021cites this paper
• The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?

  2021cites this paper
• Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments

  2020cites this paper
• Asthma: newer Tx options mean more targeted therapy.

  2020cites this paper